Bergamo Lymphoid Cancer Registry
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 6,000
- 试验地点
- 1
- 主要终点
- Overall survival
研究概览
简要总结
This registry has been established to gain a better understanding of the clinical and biological characteristics and outcome of patients with lymphoid cancer
详细描述
Lymphoid cancer including Hodgkin disease, non-Hodgkin lymphomas (NHL) and myeloma, represents the most common hematologic malignancy. Despite the overall prognosis improved in the last 10 years, there are many open issues that need to be addressed, specifically refractoriness to standard treatment, disease recurrence and outcome with new drug in the so called "real world" setting. Since the Hematology and Bone Marrow Transplant Unit at "Ospedale Papa Giovanni XIII" of Bergamo has developed specific tools to collect clinical data thought fully validated electronic charts and biological specimens thanks to a regulatory compliant biobanking program, the aim of this study is to collect clinical and biological information of lymphoid cancer patients. The cohort of patients enrolled will permit to analyze the practice pattern, perform biological correlative studies of great translational potential with relevance to clinical practice.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients 18 years or older
- •Written informed consent
- •Confirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma
排除标准
- •Unconfirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma
结局指标
主要结局
Overall survival
时间窗: 20 years
Analyzed for all patients as time from diagnosis to death as a result of any cause, stratified according to intervention and baseline characteristics
次要结局
- Progression-free survival(20 years)
- Biological correlative studies(20 years)
- Disease-free survival(20 years)
研究者
Rambaldi Alessandro
Prof.
A.O. Ospedale Papa Giovanni XXIII